Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's earnings growth outlook lacks momentum and is a weakness.
The company has insufficient levels of profitability.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 266.44 times its estimated earnings per share for the ongoing year.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The group usually releases earnings worse than estimated.